1. Sugawara Y, Hamada K, Yamada Y, Kumai J, Kanagawa M, Kobayashi K, Toda T, Negishi Y, Katagiri F, Hozumi K, Nomizu M, Kikkawa Y. Characterization of dystroglycan binding in adhesion of human induced pluripotent stem cells to laminin-511 E8 fragment. Sci Rep. 9(1): 13037, 2019, doi: 10.1038/s41598-019-49669-x. PMID: 31506597
2. Ujihara Y, Kanagawa M, Mohri S, Takatsu S, Kobayashi K, Toda T, Naruse K, Katanosaka Y. Elimination of fukutin reveals cellular and molecular pathomechanisms in muscular dystrophy-associated heart failure. Nat Commun. 2019,10(1),5754, doi: 10.1038/s41467-019-13623-2.
3. Song D, Fu X, Ge L, Chang X, Wei C, Liu J, Yang H, Qu S, Bao X, Toda T, Wu X, Xiong H. A splice site mutation c.1251G>A of ISPD gene is a common cause of congenital muscular dystrophy in Chinese patients. Clin Genet. 2020,97(5), 789-790, doi: 10.1111/cge.13695.
4. Kuwabara N, Imae R, Manya H, Tanaka T, Mizuno M, Tsumoto H, Kanagawa M, Kobayashi K, Toda T, Senda T, Endo T, Kato R. Crystal structures of fukutin-related protein (FKRP), a ribitol-phosphate transferase related to muscular dystrophy. Nat Commun. 2020,11(1),303, doi: 10.1038/s41467-019-14220-z.
5. 戸田達史.福山幸夫(1928-2014)福山型筋ジストロフィーの発見.生体の科学.2019, 70(5), 484-485.
6. 戸田達史.福山型筋ジストロフィーを含めた糖鎖合成異常症の系統的な解明と治療を目指して.脳と発達.2019,51(6),367-372.
7. 戸田達史.福山型筋ジストロフィーを含めた糖鎖合成異常症の系統的な解明・治療に関する研究.日本医師会雑誌.2019,148(9)1785-1789.
8. 戸田達史.筋ジストロフィー近年わかってきた分子機構と治療戦略.SRL宝函. 2019,40(4),12-21.
9. 久保田暁,戸田達史.先天性筋ジストロフィー(福山型先天性筋ジストロフィーを含む).今日の疾患辞典デジタル版. 2019, https://www.cds.ai/docs/detail/d09634_indd.
10. Seki T, Kanagawa M, Kobayashi K, Kowa H, Yahata N, Maruyama K, Iwata N, Inoue H, Toda T. Galectin 3-binding protein suppresses amyloid-β production by modulating β-cleavage of amyloid precursor protein. J Biol Chem. 295(11): 3678-3691, 2020, doi: 10.1074/jbc.RA119.008703. PMID: 31996371